Clinical Development
Achieve your regulatory milestone faster with better decision-making and less re-work
The stakes are never higher than in the clinical phase of your drug development program – nearly 60% of drugs entering Phase III failing to achieve regulatory approval. By providing a longitudinal evaluation of disease-specific metabolic signatures during a trial, our Targeted Metabolomics Solution enhances monitoring of individual patient response to drug metabolism and toxicity, as well as provides improved post-approval drug monitoring.
Inform adaptive trail design strategies and responses in real-time
Optimize eligibility criteria by proactively identifying responders/non-responders baseline characteristics
Dynamically monitor and optimize dose response by tracking prodromal signals of efficacy and safety
Maintain trial quality by monitoring patient compliance, subject outliers and potential food or drug-drug interactions
Strengthen post-market surveillance with a differentiated drug profile and competitor analysis
Study Design
Data Interpretation
Our Platform
